The personalized management of cancer relies on an exponential understanding of various cancer types, and of their subtypes, at both the genotypic and phenotypic levels.1 On a single molecule level, pre-clinical pharmaceutical testing in cancer cell line panels have guided early-stage clinical trials, such as with the use of gefitinib for epidermal growth factor receptor mutant lung cancers, imatinib mesylate for the fusion BCR-Abl oncogene in leukemia,2 and trastuzumab or lapatinib in HER2/ERBB2 amplified breast cancers.3, 4. Here, ERBB2 is linked to lung carcinoma.